President’s Official Congress OpeningSpeaker: Dr Brad HorsburghUpdate on 2017-2020 Strategic PlanSpeaker: Dr David Andrews, CEOUpdate on the RANZCO Communications PlanSpeaker: Ms Carr, General Manager Communi
RANDOMISED, OPEN-LABEL STUDY TO EVALUATE 2 INTRAVITREAL AFLIBERCEPT TREAT-AND-EXTEND DOSING REGIMENS IN WET AGE-RELATED MACULAR DEGENERATION: 52-WEEK OUTCOMES FROM ALTAIR
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY
N-ACETYL-CYSTEINE IN OCULAR THERAPY: A REVIEW OF THE LITERATURE
Intra Ocular Lenses – A comparison of refractive outcomes and complications
THE CLINICAL USE OF TOPICAL HYPERTONIC SALINE EYE DROPS IN A TERTIARY REFERRAL EYE CARE CENTRE IN SYDNEY, AUSTRALIA
How to. an Examination of Professional Issues Facing Ophthalmologists